Thomas Ebeling

Thomas Ebeling founded Betterlifehealthcare Ltd. in 2015, Heilpflanzenwohl AG in 2016, where he is working as Director from 2016, and Te Convest AG in 2018, where he is working as Chief Executive Officer from 2018.
Mr. Ebeling also currently works at Remagine Media Ventures, as Chairman of the Fund, Galderma Group AG, as Chairman from 2022, Sivantos, Inc. (Canada), as Director from 2016, Galderma Holding SA, as Director, Triangle Holding III SARL, as Director, SHL Medical AG, as Director, Orna Therapeutics, Inc., as Director from 2022, eClear AG, as Director, MPM BioImpact LLC, as Advisor, Schwandorfer Rohstoff- und Recycling GmbH, as Member-Supervisory Board, and Moonfare GmbH, as Board Member & Strategic Advisor from 2018.
Mr. Ebeling also formerly worked at ProSiebenSat.1 Media SE, as Chief Executive Officer from 2009 to 2017, Novartis AG, as Chief Executive Officer-Pharmaceuticals Division from 2000 to 2007, Novartis Pharmaceuticals Corp., as Chief Executive Officer from 2000 to 2007, Novartis Consumer Health, Inc., as Chief Executive Officer from 2007 to 2008, Novartis Nutrition GmbH, as Chief Executive Officer from 1998 to 2000, Auris Luxembourg III SA, as Chairman, Apleona GmbH, as Chairman-Supervisory Board, Ostbayerische Verwertungs- und Energieerzeugungsgesellschaft, as Chairman-Supervisory Board, Idenix Pharmaceuticals LLC, as Director, Lonza Group AG, as Independent Director from 2013 to 2017, PepsiCo Deutschland GmbH, as Director-National Sales & Franchise from 1994 to 1996, EQT AB, as Director, Ocean Outdoor Ltd., as Independent Non-Executive Director from 2018 to 2021, Cullinan Oncology LLC, as Independent Director, Cullinan Therapeutics, Inc., as Independent Director from 2017 to 2024, QIAGEN NV, as Member-Supervisory Board, Bayer AG, as Member-Supervisory Board from 2012 to 2019, and Reemtsma Cigarettenfabriken GmbH, as Product Manager from 1987 to 1991.
Mr. Ebeling received his undergraduate degree in 1986 from the University of Hamburg.